SUTRO BIOPHARMA, INC. (STRO) Quick Ratio
- Quick ratio · latest quarter: Value 3.22×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 3.22× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $170.14M ÷ $52.90M ≈ 3.22× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 170.14M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 52.90M USD | Liabilities, Current |
| Cash and equivalents | 54.34M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 110.01M USD | Marketable Securities, Current |
| Customer receivables | 5.80M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $170.14M | $52.90M | $54.34M | $110.01M | $5.80M | (m) | 3.22× |
| 2026-03-31 | $215.04M | $70.81M | $73.68M | $128.88M | $12.48M | (m) | 3.04× |
| 2025-12-31 | $145.41M | $75.13M | $58.13M | $83.30M | $3.98M | (m) | 1.94× |
| 2025-09-30 | $171.52M | $71.89M | $65.93M | $101.67M | $3.92M | (m) | 2.39× |
| 2025-06-30 | $213.13M | $74.25M | $64.03M | $141.11M | $8.00M | (m) | 2.87× |
| 2025-03-31 | $262.53M | $133.05M | $106.23M | $142.74M | $13.56M | (m) | 1.97× |
| 2024-12-31 | $325.51M | $131.89M | $190.30M | $126.59M | $8.62M | (m) | 2.47× |
| 2024-09-30 | $394.91M | $131.29M | $174.58M | $213.68M | $6.66M | (m) | 3.01× |
| 2024-06-30 | $382.52M | $129.99M | $90.79M | $284.78M | $6.95M | (m) | 2.94× |
| 2024-03-31 | $298.90M | $79.51M | $65.22M | $202.38M | $31.30M | (m) | 3.76× |
| 2023-12-31 | $369.76M | $93.75M | $69.27M | $264.41M | $36.08M | (m) | 3.94× |
| 2023-09-30 | $337.74M | $73.61M | $81.83M | $239.27M | $16.63M | (m) | 4.59× |
| 2023-06-30 | $368.29M | $67.13M | $235.09M | $123.20M | $10.00M | (m) | 5.49× |
| 2023-03-31 | $261.34M | $59.49M | $62.47M | $188.99M | $9.87M | (m) | 4.39× |
| 2022-12-31 | $309.47M | $66.55M | $47.25M | $255.09M | $7.12M | (m) | 4.65× |
| 2022-09-30 | $298.58M | $58.29M | $96.78M | $190.56M | $11.24M | (m) | 5.12× |
| 2022-06-30 | $289.30M | $44.57M | $79.11M | $112.51M | $97.67M | (m) | 6.49× |
| 2022-03-31 | $183.09M | $38.76M | $28.90M | $142.50M | $11.69M | (m) | 4.72× |
| 2021-12-31 | $173.21M | $41.74M | $30.41M | $130.34M | $12.45M | (m) | 4.15× |
| 2021-09-30 | $202.27M | $35.45M | $30.71M | $159.23M | $12.33M | (m) | 5.70× |
| 2021-06-30 | $232.58M | $26.13M | $56.39M | $167.03M | $9.16M | (m) | 8.90× |
| 2021-03-31 | $227.50M | $22.66M | $55.82M | $164.46M | $7.23M | (m) | 10.04× |
| 2020-12-31 | $332.05M | $29.60M | $206.15M | $120.34M | $5.56M | (m) | 11.22× |
| 2020-09-30 | $209.84M | $29.91M | $64.37M | $137.99M | $7.48M | (m) | 7.02× |
| 2020-06-30 | $206.47M | $35.46M | $65.35M | $136.01M | $5.10M | (m) | 5.82× |
| 2020-03-31 | $124.47M | $32.01M | $43.56M | $71.83M | $9.08M | (m) | 3.89× |
| 2019-12-31 | $124.16M | $32.97M | $4.96M | $112.90M | $6.30M | (m) | 3.77× |
| 2019-09-30 | $132.69M | $35.86M | $11.95M | $113.21M | $7.53M | (m) | 3.70× |
| 2019-06-30 | $159.66M | $36.10M | $19.39M | $133.77M | $6.50M | (m) | 4.42× |
| 2019-03-31 | $173.91M | $31.13M | $26.62M | $143.95M | $3.34M | (m) | 5.59× |
| 2018-12-31 | $206.98M | $36.42M | $125.30M | $79.19M | $2.49M | (m) | 5.68× |
| 2018-09-30 | $125.39M | $36.91M | $41.35M | $81.60M | $2.44M | (m) | 3.40× |
| 2018-06-30 | (m) | (m) | $25.42M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | $6.63M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $31.96M | $22.02M | (m) | $1.62M | (m) | (m) |
| 2017-09-30 | (m) | (m) | $25.41M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | $11.59M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |